A new muscle science and disease research center has opened at the University of Washington (UW) to investigate better treatment options for disorders such as amyotrophic lateral sclerosis (ALS). The Center for Translational Muscle Research will work in collaboration with the university’s labs and other Seattle-area institutions…
Target ALS joined with the Association for Frontotemporal Degeneration (AFTD) to announce a $5 million grant initiative to spur the development of new therapies and identify biomarkers for both amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD). Project proposals are welcomed from “Industry-Led Consortia (ILCs)” that bring together…
ALS is now affecting my husband’s breathing. On occasion, Todd’s lungs fill with fluid and he needs me to give him an assisted cough, just as his physical therapist taught me to do. He stacks his breath as I count to four, and I push on his abdomen below…
AL-S Pharma AG, a biotech company jointly founded and financed by Neurimmune and TVM Capital Life Science, has enrolled the first patient in its Phase 1 clinical trial assessing the safety and tolerability of AP-101, an experimental therapy for amyotrophic lateral sclerosis (ALS). AP-101 is a human…
About a week after my initial ALS diagnosis, the crippling fog that it had produced lifted enough for me to seek a second opinion. The appointment took place at the neurology department at the University of North Carolina…
Collaborative Medicinal Development (CMD) has enrolled the first patient in its Phase 2/3 clinical trial assessing the safety and efficacy of CuATSM, an investigational therapy for amyotrophic lateral sclerosis (ALS). The trial (NCT04082832) is aimed at evaluating the efficacy and safety of CuATSM. The…
Mexiletine, an oral medicine to treat irregular heartbeats, is safe and effective for reducing muscle cramps in patients with amyotrophic lateral sclerosis (ALS), results from a Phase 4 clinical trial show. To date, this is the only treatment shown to reduce both the number and intensity of cramps…
BrainStorm Cell Therapeutics announced that the Phase 3 clinical trial of its cell therapy candidate NurOwn in 200 amyotrophic lateral sclerosis (ALS) patients is fully enrolled and treatment is underway. The randomized, double-blind and multicenter trial (NCT03280056) is assessing the safety and effectiveness of three administrations of NurOwn into…
A Harvard Medical School professor and scientist, Sabrina Paganoni, has won the 2019 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Scientific Impact Award for her work in a Phase 2a trial testing fingolimod as a potential treatment for amyotrophic lateral sclerosis (ALS). Fingolimod is marketed as Gilenya (by Novartis), an…
Before my husband, Todd, got ALS, we had minor problems, but we were full of hope. We had a small baby so I wasn’t getting much sleep, but I knew that things would get better. Todd was sometimes frustrated with his work, but he hoped to be promoted. Our obstacles…
Get regular updates to your inbox.
